Analysts Issue Forecasts for FOLD Q2 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Stock analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Amicus Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz anticipates that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.04 EPS.

Several other research firms also recently weighed in on FOLD. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Bank of America raised their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Finally, Guggenheim lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $9.51 on Tuesday. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The firm has a 50-day moving average price of $9.66 and a two-hundred day moving average price of $10.52. Amicus Therapeutics has a twelve month low of $8.78 and a twelve month high of $14.03. The company has a market capitalization of $2.84 billion, a P/E ratio of -27.97, a price-to-earnings-growth ratio of 1.43 and a beta of 0.62.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have sold 22,901 shares of company stock valued at $259,863. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Xponance Inc. boosted its holdings in shares of Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its holdings in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the last quarter. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $26,000. Finally, AlphaCentric Advisors LLC lifted its holdings in shares of Amicus Therapeutics by 1.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock valued at $2,189,000 after acquiring an additional 2,500 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.